ARTICLE | Company News
Medical Marketing, Provalis cancer deal
October 11, 2001 7:00 AM UTC
Medical Marketing International ( Cambridge, U.K.) received exclusive rights to develop CCX2 plant-derived cancer therapy from Provalis (LSE:PRO). MMI said that in a mouse model using human ovarian ce...